What is the price target for DERM stock?
10 analysts have analysed DERM and the average price target is 13.77 USD. This implies a price increase of 107.69% is expected in the next year compared to the current price of 6.63.
JOURNEY MEDICAL CORP (DERM) Forecast, Price Target & Analyst Ratings
NASDAQ:DERM • US48115J1097
Current stock price
6.63 USD
-0.32 (-4.6%)
At close:
6.76 USD
+0.13 (+1.96%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for JOURNEY MEDICAL CORP (DERM).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.06
- Revenue Estimate
- 19.24M
Price Target Details & History
Consensus Price Target and Range
Mean target
$13.77
Upside
+ 107.69%
From current price of $6.63 to mean target of $13.77, Based on 10 analyst forecasts
Low
$12.12
Median
$13.26
High
$16.80
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for DERM. The average price target is 13.77 USD. This implies a price increase of 107.69% is expected in the next year compared to the current price of 6.63.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.00%
DERM was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about DERM.
In the previous month the buy percentage consensus was at a similar level.
DERM was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-25 | HC Wainwright & Co. | Initiate | Buy |
| 2025-08-13 | Lake Street | Maintains | Buy -> Buy |
| 2025-07-30 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-09-06 | Lake Street | Initiate | Buy |
| 2024-08-22 | Rodman & Renshaw | Initiate | Buy |
| 2024-06-28 | Roth MKM | Reiterate | Buy |
| 2024-02-16 | Alliance Global Partners | Initiate | Buy |
| 2023-09-07 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2023-07-12 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-05-23 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-03-30 | B. Riley Securities | Reiterate | Buy |
| 2022-02-25 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-12-16 | Roth Capital | Initiate | Buy |
| 2021-12-07 | B. Riley Securities | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.06
- Revenue Estimate
- 19.24M
- Revenue Q2Q
- 41.26%
- EPS Q2Q
- 60.90%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-2.46%
EPS (1 Month)
0.00%
EPS (3 Months)
-27.78%
Next Earnings Summary
DERM is expected to report earnings on 3/25/2026. The consensus EPS estimate for the next earnings is -0.06 USD and the consensus revenue estimate is 19.24M USD.
The next earnings revenue estimate has been revised downward by 2.46% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 73.67M 16.70% | 79.181M 7.48% | 56.134M -29.11% | 65.945M 17.48% | 102.76M 55.83% | 157.16M 52.94% | |
| EBITDA YoY % growth | -23.24M 28.29% | 4.837M 120.81% | -14.806M -406.10% | 2.28M 115.40% | 21.625M 848.46% | 83.044M 284.02% | |
| EBIT YoY % growth | -27.52M 21.10% | 1.07M 103.89% | -18.23M -1,803.74% | -8.637M 52.62% | 10.306M 219.32% | 43.851M 325.49% | |
| Operating Margin | -37.36% | 1.35% | -32.48% | -13.10% | 10.03% | 27.90% | |
| EPS YoY % growth | -1.68 37.14% | -0.18 89.29% | -1.02 -466.67% | -0.49 52.00% | 0.26 152.60% | 1.30 404.95% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.06 60.90% | -0.03 83.00% | 0.05 131.88% | 0.15 270.00% | 0.14 343.48% |
| Revenue Q2Q % growth | 19.24M 41.26% | 20.829M 58.53% | 25.379M 69.09% | 29.625M 68.03% | 31.405M 63.23% |
| EBITDA Q2Q % growth | 1.973M 78.55% | 2.555M 213.10% | 5.051M 776.17% | 7.958M 378.25% | 7.796M 295.13% |
| EBIT Q2Q % growth | -773.16K 66.66% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
48.50%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
39.53%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
84.38%
EBIT Next 5 Year
N/A
JOURNEY MEDICAL CORP / DERM Forecast FAQ
Can you provide the upcoming earnings date for JOURNEY MEDICAL CORP?
JOURNEY MEDICAL CORP (DERM) will report earnings on 2026-03-25, after the market close.
What are the consensus estimates for DERM stock next earnings?
The consensus EPS estimate for the next earnings of JOURNEY MEDICAL CORP (DERM) is -0.06 USD and the consensus revenue estimate is 19.24M USD.
How do analysts rate JOURNEY MEDICAL CORP (DERM)?
The consensus rating for JOURNEY MEDICAL CORP (DERM) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.